Endothelial Activation and Stress Index in Different Types of Hypertensive Pregnancy Disorders Authors: Anna S Scholz, Lena Büchler, Annabel Kussner, Kristina Killinger, Hannah Arndt, Michael Elsässer, Thomas Luft, Cahit Birdir, Stephanie Wallwiener, Alexandra von Au Published: 2026 ABSTRACT AbstractBackgroundEndothelial dysfunction is a major contributor to the pathophysiology of preeclampsia and can be quantified by the simple formula, lactate dehydrogenase×creatinine/thrombocytes, termed the Endothelial Activation and Stress Index (EASIX). We evaluated EASIX in hypertensive disorders of pregnancy and its value in the assessment of preeclampsia.MethodsThis retrospective study included 465 patients with preeclampsia, 197 with chronic or gestational hypertension, and 894 controls who delivered at Heidelberg University Hospital between 2017 and 2022. Propensity score matching was used to balance confounding variables. A total of 3732 EASIX values were available for the analysis.ResultsThe mean age was 31.8±5.6 years (preeclampsia), 32.9±5.3 years (hypertension), and 31.7±5.8 years (controls). EASIX was significantly higher in patients with preeclampsia as compared with patients with hypertension (0.94±0.58 versus 0.60±0.28, P<0.001) and with controls (0.94±0.58 versus 0.55±0.23, P<0.001). The diagnostic accuracy of EASIX for a diagnosis of preeclampsia yielded an area under the curve of 0.76 (0.73–0.79, P<0.001). A high number of end‐organ manifestations in patients with preeclampsia was associated with higher EASIX. Analyses of EASIX trajectories across gestation showed an increase of +30.8% in normotensive patients, whereas EASIX levels did not differ in preeclampsia before versus after 34 weeks (0.94±0.60 versus 0.95±0.57, P=0.65).ConclusionsEASIX is a simple marker that could potentially discriminate patients with preeclampsia from healthy controls. We propose that EASIX may serve as a promising additional biomarker in the assessment of preeclampsia, prompting us to explore its incorporation in potential combined biomarker models in clinical routine.Keywords: endothelial dysfunction, elevated liver enzymes, hemolysis, low platelets syndrome, prediction, preeclampsiaSubject Categories: Vascular Disease, High Blood Pressure, Hypertension, Preeclampsia, Biomarkers Nonstandard Abbreviations and Acronyms Endothelial Activation and Stress Index glutamic oxaloacetic transaminase placental growth factor soluble fms‐like tyrosine kinase‐1 Research Perspective What Is New? The novelty of our work includes the first systematic characterization of Endothelial Activation and Stress Index trajectories across gestation in different subtypes of hypertensive disorders of pregnancy. The novelty of our work includes the first systematic characterization of Endothelial Activation and Stress Index trajectories across gestation in different subtypes of hypertensive disorders of pregnancy. We show that the Endothelial Activation and Stress Index is significantly higher in women with preeclampsia compared with hypertensive and normotensive pregnancies, demonstrating its ability to discriminate between different types of hypertensive disorders of pregnancy. We show that the Endothelial Activation and Stress Index is significantly higher in women with preeclampsia compared with hypertensive and normotensive pregnancies, demonstrating its ability to discriminate between different types of hypertensive disorders of pregnancy. What Question Should Be Addressed Next? Our findings support the Endothelial Activation and Stress Index as a promising biomarker in the context of hypertensive disorders of pregnancy. Future studies are needed to validate our findings and to precisely define the synergies and overlaps between existing biomarkers in clinical practice. Our findings support the Endothelial Activation and Stress Index as a promising biomarker in the context of hypertensive disorders of pregnancy. Future studies are needed to validate our findings and to precisely define the synergies and overlaps between existing biomarkers in clinical practice. Hypertensive disorders of pregnancy (HDP) affect up to 10% of all pregnancies 1 and summarize the diagnoses of de novo or superimposed preeclampsia, gestational hypertension, and chronic hypertension. 2 However, the group of HDP is highly heterogeneous, and the single entities exhibit distinct clinical, laboratory, and prognostic characteristics. Whereas gestational hypertension is defined by new‐onset hypertension after 20 weeks of gestation without proteinuria or end‐organ damage, preeclampsia is additionally characterized by proteinuria, thrombocytopenia, impaired renal or liver function, or uteroplacental dysfunction and carries a significantly higher risk of maternal and fetal morbidity. 3 These differences were recently highlighted by Alhuneafat et al, who performed echocardiographic examinations during and up to 1 year postpartum, revealing graded differences in left ventricular remodeling across the entities of HDP. 4 Interestingly, the most pronounced abnormalities were found in patients with superimposed preeclampsia, whereas gestational hypertension did not differ from normal controls. Pregnancy is often viewed as a window of opportunity because it is a natural vascular stress test. 5 A history of HDP is associated with an increased risk for short‐term and long‐term vascular complications such as myocardial infarction, stroke, and terminal renal insufficiency. 6 , 7 , 8 When stratifying for the subgroups of HDP, the highest risk for stroke was found in patients with superimposed preeclampsia. 9 Although it is widely accepted that HDP are associated with dysregulated inflammatory responses to pregnancy, 10 preeclampsia is the most severe form of HDP, which involves systemic organ manifestations additionally to hypertension. 2 Endothelial dysfunction is one of the key pathophysiological factors that link preeclampsia with many other diseases. The Endothelial Activation and Stress Index (EASIX), has been introduced as a universal marker of systemic endothelial dysfunction based on the parameters lactate dehydrogenase, creatinine, and platelet count. 11 EASIX was initially developed and validated as a prognostic marker for endothelial‐related complications after allogenic stem cell transplantation. 12 , 13 In further studies, elevated EASIX scores were independently associated with increased risk of adverse outcomes, including mortality in coronary heart disease, 14 diabetic nephropathy, 15 stroke, 16 and COVID‐19 disease. 17 Our group previously demonstrated that EASIX is significantly associated with adverse outcomes in patients with preeclampsia and may support clinical risk stratification. 18 EASIX quantifies the degree of endothelial activation and stress by integrating routine laboratory markers, which are direct consequences of platelet consumption (low thrombocytes), hemolysis (elevated lactate dehydrogenase), and impaired renal function (elevated creatinine) that characterize preeclampsia. 19 However, we lack information on EASIX in other subgroups of HDP and a healthy pregnant population. EASIX is expected to differ across subtypes of HDP based on their distinct pathophysiological profiles. Although preeclampsia is typically defined as a multiorgan disease arising from systemic endothelial dysfunction driven by placental ischemia and the release of antiangiogenic factors, gestational hypertension induces a less pronounced degree of endothelial dysfunction and typically lacks the multiorgan involvement that would drive EASIX levels upward. In contrast, chronic hypertension reflects longstanding preexisting vascular remodeling rather than acute endothelial stress triggered by the placenta and would therefore be expected to differ from both preeclampsia and gestational hypertension in its EASIX values. In this study, we therefore evaluated EASIX in different types of hypertensive disorders in pregnancy and aimed to characterize EASIX trajectories across gestation in healthy, normotensive pregnancies. Additionally, we tested the capacity of EASIX to differentiate between healthy and preeclamptic pregnancies. METHODS Study Design and Population This retrospective single‐center study was conducted using routinely documented data from the Department of Gynecology and Obstetrics at the University Hospital Heidelberg, Germany. Approval was obtained from the local ethics committee of the medical faculty of Ruprecht‐Karls University Heidelberg (S‐680/2023). An exemption from requiring informed consent was granted because all data were collected retrospectively. The data that support the findings of this study are available from the corresponding author upon reasonable request. Eligible for inclusion were all women who gave birth at our institution between 2017 and 2022 and for whom at least 1 laboratory result was available during pregnancy that allowed calculation of the EASIX score. The EASIX score was determined as follows: (lactate dehydrogenase [U/L]×creatinine [mg/dL])/platelet count (cells/nL). The detailed inclusion and exclusion criteria have been published previously. 18 In brief, women with conditions that might influence the EASIX score, such as significant renal or cardiovascular disease or SARS‐CoV‐2 infection during pregnancy, were not included. Exclusion criteria were fetal chromosomal, genetic, or structural abnormalities, as well as incomplete data sets. Multiple pregnancies were analyzed separately and were excluded for the main analyses. Hypertensive disorders of pregnancy (preeclampsia, chronic hypertension, and gestational hypertension) were classified in accordance with the 2021 guidelines of the International Society for the Study of Hypertension in Pregnancy. 2 Further exclusion criteria for the normotensive control group were any forms of hypertension, hemolysis, elevated liver enzymes, low platelets syndrome; eclampsia; and fetal growth retardation at any time point during the index pregnancy. Statistical Analysis For the development of gestational age‐dependent centile distributions, we defined 6 gestational age intervals: <20 weeks, weeks 20 to 23, weeks 24 to 28, weeks 29 to 33, weeks 34 to 36, and weeks ≥37 to delivery. Gestational age windows were defined according to established clinical thresholds at 24+0 weeks (limit of viability), 34+0 weeks (early versus late preeclampsia), and 37+0 weeks of gestation (preterm birth). Only the first available EASIX value per patient and gestational age window was selected. Consequently, each patient contributed at most 1 EASIX value per gestational age window, preserving the independence of observations within each interval. The following 3 groups were compared: (1) patients with preeclampsia, (2) patients with either chronic hypertension or gestational hypertension (further labeled as hypertension), and (3) patients with normotensive pregnancies (further labeled as controls). Scatter plots were generated to visualize EASIX in the 3 groups across the gestational period. For the comparisons among the 3 groups, only the first available EASIX value after diagnosis of a hypertensive disorder of pregnancy was used. In cases of patients with chronic hypertension, the first available EASIX value in the current pregnancy was used for the analysis. The first EASIX value after diagnosis was selected to minimize confounding by disease progression. Propensity score matching was created to balance the groups across confounding variables. These confounders were defined previously according to their potential clinical effect on the EASIX ratio and included body mass index, age, gestational weeks at EASIX measurement, current smoking status, gestational diabetes, and the intake of aspirin. Patients with missing data on these covariates were excluded (n=18 in the preeclampsia group and n=10 in the hypertension group). To conduct the adjustment based on propensity scores, we used logistic regression models. The preeclampsia group and the hypertension group were each matched 1:1 to the control group based on propensity scores to their nearest neighbors without replacement. The covariate balance was checked by standardized mean differences for each covariate and was considered well balanced across the groups if the standardized mean difference was <0.1. Before and after propensity score matching, we calculated the mean±SD for continuous variables and frequencies for continuous variables in each group. In addition, the Kolmogorov‐Smirnov test was used to assess distributional balance. For matching between the control group and patients with preeclampsia, the test yielded P<0.001 before and P=0.9995 after matching, indicating an improvement of covariate distribution. For matching between the control group and patients with hypertension, the test indicated P<0.001 before and P=1.0 after matching. Visual inspection of quantile‐quantile plots and the Kolmogorov‐Smirnov and Shapiro‐Wilk tests were applied to assess whether EASIX followed a normal distribution. Because EASIX was not normally distributed, a Wilcoxon signed‐rank test was used for the comparison among the groups. P values <0.05 were considered statistically significant. Receiver operating characteristic curve analyses were performed to evaluate the discriminatory power of EASIX levels for the diagnosis of preeclampsia based on propensity score‐matched cohorts. Receiver operating characteristic curve analyses were additionally performed in the subgroups of early‐ and late‐onset preeclampsia defined as before or after 34 weeks of gestation. The optimal threshold was calculated based on the maximized Youden index. 20 The correlation between EASIX and clinical variables was evaluated using the Pearson correlation coefficient. Statistical analyses were conducted in IBM SPSS Statistics 29.0.2.0 (IBM, Armonk, NY), RStudio 2025.09.1+401 (Posit Software PBC, Boston, MA), and Prism 9.5.0 (GraphPad Prism Software, San Diego, CA). RESULTS Study Population The cohort included 465 patients with preeclampsia, 197 with hypertension, and 894 control patients (see Figure S1). Based on propensity scores, 2 comparisons were performed: (1) Each patient in the preeclampsia group was matched in a 1:1 manner to a control patient. (2) Each patient in the hypertension group, including both chronic and gestational hypertension, was matched in a 1:1 manner to a control patient. We combined the groups of chronic and gestational hypertension, because the number of cases was too low for individual analyses, and the EASIX value was not significantly different in the 2 groups (chronic hypertension: 0.57±0.27, gestational hypertension: 0.63±0.29; P=0.073). Baseline patient characteristics before and after propensity score matching are presented in Tables 1 and 2. Further baseline characteristics are reported in Table S1. Before weighting, the characteristics that showed the highest standard mean differences were body mass index (28±7.2 versus 26.2±6.2) and the gestational age at the EASIX measurement (34.5 weeks versus 33.9 weeks). Comparing the group of hypertension and the control group, the main differences were found for maternal age (32.9 versus 31.7 years) and intake of aspirin (14.2% versus 8.4%), as well as for body mass index (30.5 versus 26.2) and gestational age at measurement (35.2 weeks versus 33.9 weeks). After propensity score matching, the covariates appeared to be well balanced, with standardized mean differences of <0.1 (see Figure S2). However, unmeasured confounding variables may still exist. Table 1Propensity Score Matching Comparing the Group of Preeclampsia Versus ControlsVariableBefore propensity score matchingAfter propensity score matchingControlsPreeclampsiaSMDControlsPreeclampsiaSMDNo.894465465465Body mass index, kg/m2 26.2±6.228±7.20.25727.8±6.828±7.20.025Smoking, n (%)72 (8.1)21 (4.5)−0.17023 (4.95)21 (4.5)−0.021Age, y31.7±5.831.8±5.60.02731.7±5.831.8±5.60.022Gestational diabetes, n (%)184 (20.6)86 (18.5)−0.05488 (18.9)86 (18.5)−0.011Gestational age, wk33.9±7.234.5±3.90.17134.73±6.334.5±3.9−0.053Intake of aspirin, n (%)75 (8.4)38 (8.2)−0.00835 (7.5)38 (8.2)0.024Data are presented as either absolute (relative) numbers (percent) or mean±SD.SMD indicates standardized mean difference. Propensity Score Matching Comparing the Group of Preeclampsia Versus Controls Data are presented as either absolute (relative) numbers (percent) or mean±SD. SMD indicates standardized mean difference. Table 2Propensity Score Matching Comparing the Group of Hypertension Versus ControlsVariableBefore propensity score matchingAfter propensity score matchingControlsHypertensionSMDControlsHypertensionSMDNo.894197197197Body mass index, kg/m2 26.2±6.230.5±8.10.53929.9±7.630.5±8.10.073Smoking, n (%)72 (8.1)15 (7.6)−0.01713 (6.6)15 (7.6)0.038Age, y31.7±5.832.9±5.30.22833.4±5.932.9±5.3−0.104Gestational diabetes, n (%)184 (20.6)39 (19.8)−0.02038 (19.3)39 (19.8)0.013Gestational age, wk33.9±7.235.2±5.90.22935.3±5.035.2±5.9−0.021Intake of aspirin, n (%)75 (8.4)28 (14.2)0.16719 (14.7)28 (14.2)−0.015Data are presented as either absolute (relative) numbers (percent) or mean±SD.SMD indicates standardized mean difference. Propensity Score Matching Comparing the Group of Hypertension Versus Controls Data are presented as either absolute (relative) numbers (percent) or mean±SD. SMD indicates standardized mean difference. Centile Distributions of EASIX in Normotensive Pregnancies Our first aim was to evaluate the relationship between EASIX values and gestational age in healthy control patients. Each patient could contribute at most 1 measurement per gestational age interval for the analysis. In total, 1469 EASIX measurements of all 941 control patients were available. Table 3 shows quantile calculations of EASIX in the 6 predefined gestational age intervals. To evaluate the dynamics of EASIX values across gestation, we chose to compare the earliest (<20 weeks) versus the latest gestational age window (>37 weeks) in patients with available values in both intervals (n=27). EASIX showed a significant increase across gestation (0.43±0.13 versus 0.58±0.16, paired Wilcoxon signed‐rank test: P<0.001). Table 3Quantile Calculations of EASIX in Normotensive Control Patients Stratified by Gestational Age IntervalsGA intervalNumber of measurementsPercentiles2.5510255075909597.5<20+0580.1790.2230.2760.3190.4180.5130.6450.7040.75920+0–23+6530.1810.2170.2350.2820.4310.5900.6700.7211.06524+0–28+61350.1910.2130.2390.2810.4110.5130.6140.7040.78529+0–33+62720.1850.2180.2580.3310.4450.5730.7010.7390.81734+0–36+63390.210.2540.2890.3780.50.6490.8460.9391.109≥37+06120.2580.2970.3370.4330.5590.7310.9021.0421.161EASIX values in 1469 measurements from 941 singleton pregnancies were analyzed within 6 predefined GA intervals.EASIX indicates Endothelial Activation and Stress Index; and GA gestational age. Quantile Calculations of EASIX in Normotensive Control Patients Stratified by Gestational Age Intervals EASIX values in 1469 measurements from 941 singleton pregnancies were analyzed within 6 predefined GA intervals. EASIX indicates Endothelial Activation and Stress Index; and GA gestational age. Assessment of EASIX in Different Subsets of Hypertensive Disorders Figure 1 illustrates all individual EASIX values across gestation among the preeclampsia, hypertension, and control group that were available before propensity score matching. In addition to the 1469 EASIX measurements of the control patients, the scatterplot includes 1942 EASIX measurements of 483 patients with preeclampsia and 327 values of 207 patients with hypertension. The splines‐based curves represent the estimated means of EASIX across gestation. In the control group, EASIX values increased with a slight U‐shaped curve, with the lowest EASIX values during 24 and 28 weeks of gestation (gray line in Figure 1). Analyzing the trajectories of EASIX between the second and third trimester showed a 30.8% increase in patients who were normotensive and a 26.4% increase in patients in the hypertension group. In contrast, EASIX values among patients with preeclampsia stayed on a relatively stable level across gestation (preeclampsia: 4.7% decrease between the second and third trimester). The trajectories of the individual parameters of EASIX across gestation are shown in Figure S3. In the control group, both lactate dehydrogenase (205±44 versus 228±46), creatinine (0.49±0.09 versus 0.53±0.11), and thrombocytes (245±61 versus 236±65) changed significantly between the second and third trimester (for each comparison P<0.001). Scatterplots of EASIX values of all patients with preeclampsia (n=483), chronic hypertension/gestational hypertension (n=207), and normotensive pregnancies (n=941) across the weeks of gestation. In total, the plot depicts 1942 EASIX measurements in patients with preeclampsia, 327 measurements in patients with hypertension, and 1469 measurements in patients who were normotensive. EASIX indicates Endothelial Activation and Stress Index. For the comparison of EASIX among the 3 groups, only the first available EASIX value was included in the analysis, and patient groups were matched based on propensity scores. Patients with preeclampsia presented with significantly higher EASIX values compared with control patients (before matching: 0.94±0.58 versus 0.54±0.22, P<0.001; after propensity score matching: 0.94±0.58 versus 0.55±0.23, P<0.001) and compared with patients who were hypertensive (0.60±0.28, P<0.001) (Figure 2A). EASIX values in patients with hypertension were significantly higher than in control patients (before matching: P=0.003; after propensity score matching: 0.60±0.28 versus 0.54±0.25, P=0.012) (Figure 2A). Comparison of EASIX values in patients with preeclampsia (n=465), hypertension (n=197), and normotensive pregnancies (n=894). A, Total cohort. B, Stratified by gestational age intervals <34 weeks and ≥34 weeks. Darker colors indicate patients <34 weeks, and lighter colors indicate patients ≥34 weeks. Boxes mark the median and interquartile range. Whiskers represent the 2.5th and 97.5th percentiles. Presented data refer to patient groups before propensity score matching. EASIX indicates Endothelial Activation and Stress Index; and ns, not significant. In the next step, we analyzed EASIX in the 2 clinically relevant time frames before 34 and after 34 weeks of gestation (Figure 2B). Patients with preeclampsia had significantly higher EASIX levels as compared with controls <34 weeks (0.94±0.58 versus 0.46±0.17, P<0.001) as well as >34 weeks (0.94±0.59 versus 0.58±0.24, P<0.001). There was no significant difference between EASIX levels in the preeclampsia group before versus after 34 weeks (0.94±0.60 versus 0.95±0.57, P=0.65). In the interval >34 weeks, patients with hypertension had significantly increased EASIX levels as compared with patients with hypertension <34 weeks (0.63±0.28 versus 0.49±0.2, P=0.016). Control patients showed a significant increase in EASIX levels in the interval ≥34 weeks compared with control subjects <34 weeks (0.58±0.24 versus 0.46±0.17, P<0.0001) (Figure 2B). We then stratified the patients with preeclampsia based on severity according to the number of affected end‐organs. Patients with at least 3 end‐organ manifestations had the highest mean EASIX values of 1.68±0.90, which differed significantly compared with those patients with only 2 (1.1±0.57, P=0.008) or only 1 end‐organ manifestation (0.74±0.35, P<0.001) (Figure 3). Comparison of EASIX values in patients with preeclampsia stratified by the number of end‐organ manifestations vs the propensity score‐matched control group (n=465). Boxes mark the median and interquartile range. Whiskers represent the 2.5th and 97.5th percentiles. EASIX indicates Endothelial Activation and Stress Index. EASIX in the Context of Other Clinical and Laboratory Parameters We next performed correlation analyses to further characterize EASIX in the context of clinical and laboratory parameters in patients with preeclampsia (Table S2). We found a moderate correlation between EASIX and systolic blood pressure in the preeclampsia group (r=0.22, P=0.001). EASIX was significantly correlated to maternal age (r=0.12, P=0.011). Furthermore, EASIX levels correlated with GOT (glutamic oxaloacetic transaminase) (r=0.51, P<0.001) and CRP (C‐reactive protein) (r=0.2, P<0.001). We found a significant inverse correlation between EASIX and body mass index (r=−0.17, P<0.001). However, EASIX levels did not differ significantly between patients with versus without gestational diabetes (0.85±0.49 versus 0.96±0.6, P=0.11). Interestingly, patients who were actively smoking during pregnancy (n=21) and those with aspirin medication (n=38) presented with significantly lower EASIX levels compared with nonsmokers (0.79±0.71 versus 0.95±0.58, P=0.02) and patients without aspirin (0.77±0.50 versus 0.95±0.59, P=0.025), respectively. For the main analysis, we excluded multiple pregnancies. However, we performed a subanalysis to gain further insights on the pathophysiology of preeclampsia and EASIX in multiples. Mean EASIX levels differed significantly between twin and singleton pregnancies in the total cohort (0.798±0.58 versus 0.67±0.42, P=0.003). Consistent with the abovementioned findings in singletons, EASIX levels in multiples were significantly higher in preeclampsia (n=57) compared with controls (n=89) (1.13±0.80 versus 0.59±0.27, P<0.001). Diagnostic Accuracy of EASIX in Preeclampsia Receiver operating characteristic curves were generated to assess the diagnostic accuracy of EASIX for a diagnosis of preeclampsia. The area under the curve (AUC) for EASIX was 0.76 (95% CI, 0.73–0.79; P<0.001). In the subgroups of early‐ and late‐onset preeclampsia, EASIX yielded an AUC of 0.82 (95% CI, 0.79–0.87; P<0.001) and 0.73 (95% CI, 0.69–0.77; P<0.001), respectively (Figure S4). Receiver operating characteristic curves for the individual parameters of EASIX are shown in Figure S5. The discriminatory accuracy of EASIX seemed to be mainly driven by creatinine (AUC, 0.75 [95% CI, 0.73–0.78]) and lactate dehydrogenase (AUC, 0.74 [95% CI, 0.71–0.77]), whereas platelet counts revealed a lower AUC of 0.59 (95% CI, 0.56–0.62). Using the Youden index, we derived the optimal diagnostic threshold for diagnosis of preeclampsia to be EASIX=0.606, yielding a sensitivity of 0.69 (95% CI, 0.65–0.73) and specificity of 0.70 (95% CI, 0.66–0.94). When applied to differentiate early‐onset preeclampsia from control patients, this threshold achieved a sensitivity of 0.70 and a specificity of 0.83. DISCUSSION The main finding of our study is that EASIX, calculated by the standard laboratory parameters lactate dehydrogenase, creatinine, and thrombocytes, is significantly higher in women with preeclampsia compared with hypertensive and normotensive control patients. This study represents the first systematic evaluation of EASIX across the subtypes of hypertensive disorders of pregnancy. Our data demonstrate that EASIX provides considerable discriminatory ability to distinguish women with preeclampsia from normotensive controls, and offer gestational age‐stratified distribution data that may serve as a foundation for future diagnostic applications in obstetric care. Our data support EASIX as a new promising marker in obstetrics representing distinct pathways of systemic endothelial impairment that are involved in the pathophysiology of preeclampsia. 18 Given the pronounced heterogeneity of endothelial responses, a single biomarker is often insufficient to reflect the global consequences of endothelial activation and dysfunction. In contrast, EASIX combines routine laboratory parameters that individually reflect different aspects of endothelial dysfunction: (1) Alterations in renal function are reflected by high creatinine levels, because endothelial pathology is typically linked to conditions such as glomerulonephritis, acute renal failure, and nephropathy. (2) Elevated lactate dehydrogenase serves as an indicator of cellular damage resulting from higher turnover of circulating cells. (3) The endothelium‐mediated activation of platelets leads to thrombosis and finally to the consumption of platelets. Although EASIX has been described as a validated prognostic marker for many nonobstetric diseases like coronary heart disease 14 and COVID‐19 infection, 17 there are only 2 studies investigating EASIX in pregnancy. Our group recently introduced EASIX as a predictive marker of preeclampsia‐related maternal and perinatal adverse outcomes. 18 We have shown that patients with high EASIX levels were more likely to develop adverse outcomes and had a shorter remaining time until delivery. 18 A study group from Turkey investigated EASIX in patients with intrahepatic cholestasis in pregnancy and found increased levels compared with healthy controls. 21 Their control group had median EASIX levels of 0.4 at a mean gestational age of 32 weeks. These results fit to the median EASIX levels of our normotensive control group in this gestational age interval (29 + 0–33 + 6 weeks: 0.445). Based on our large cohort of patients who were normotensive and had available EASIX values, we reported centile distributions for EASIX in relation to gestational age intervals. Analyses of the EASIX trajectories across gestation showed an EASIX increase of +30.8% in patients who were normotensive. It is widely accepted that pregnancy itself acts as a stress test to the endothelium. 22 An increase in EASIX during healthy pregnancies does not necessarily indicate pathological endothelial function but may reflect the continuous physiological adaptations of the vasculature in response to inflammatory and immunological challenges triggered by pregnancy. A comparable rising course during pregnancy has been reported for other biomarkers, such as sFlt1 (soluble fms‐like tyrosine kinase‐1) to PIGF (placenta growth factor) ratio and high‐sensitivity cardiac troponin I. The lowest values of the sFlt‐1/PlGF ratio were observed in weeks 24 to 28, whereas higher values occurred at the end of normotensive pregnancies. 23 Bacmeister et al investigated high‐sensitivity cardiac troponin I in women without preeclampsia and found a relative increase of 28% of high‐sensitivity cardiac troponin I in the third trimester compared with the first trimester. 24 With ongoing pregnancy, blood volume expansion and increasing cardiac output seem to dictate profound physiological cardiovascular adaptations, which may be mirrored by shifts in cardiac biomarkers and EASIX levels even in healthy pregnancies. Outside of pregnancy, EASIX was shown to correlate with cardiac biomarkers like NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) and troponin T. 14 In patients with preeclampsia, there was no significant difference in EASIX before versus after 34 weeks of gestation. We hypothesize that once a certain threshold is reached, the manifestation of preeclampsia may be associated with an insufficient endothelial capacity to endure the physiological vascular and inflammatory challenges during pregnancy. 25 Thereby, EASIX may reflect the individual predisposition and endothelial vulnerability of becoming dysfunctional after a challenging event such as a pregnancy. 19 Additionally, EASIX was associated with the number of end‐organ manifestations in preeclampsia in our cohort, suggesting that EASIX may mirror the extent of the endothelial stress in preeclampsia. Edvinsson et al found that the severity of preeclampsia was significantly associated with syndecan‐1, representing the endothelial protective glycocalyx layer and thus its integrity. 26 Higher circulating syndecan‐1 levels indicated disruption of the endothelial barrier and shedding of the glycocalyx and supported the concept of severe endothelial injury in preeclampsia. This finding fits with our observation of significantly increased EASIX levels with greater end‐organ involvement and bears the chance for individualized clinical monitoring and risk anticipation. EASIX yielded a moderate diagnostic performance with an AUC of 0.76 for the diagnosis of preeclampsia. To date, the most commonly used biomarker in clinical routine is the sFlt‐1/PlGF ratio, which can accurately identify patients with preeclampsia with an AUC of 0.95. 23 However, measurement and calculation of EASIX is significantly less time‐ and cost‐consuming and can be easily implemented at all laboratories. Given the retrospective design of our study, we cannot provide comparisons of these 2 biomarkers for our cohort. Indirectly, there is evidence that supports a potential link between EASIX and the sFlt‐1/PlGF ratio, as the sFlt‐1/PlGF ratio was shown to correlate with the individual parameters of EASIX. The sFlt‐1/PlGF ratio yielded a moderate correlation to creatinine (0.55) 27 and an inverse mild correlation to thrombocytes (−0.27, P<0.05). 28 A recent in vitro study provided deeper insights into the strong link between the angiogenic imbalance and endothelial dysfunction, because it showed that rising levels of the sFlt‐1/PlGF ratio lead to mitochondrial dysfunction in endothelial cells, increasing lactate dehydrogenase levels and oxidative stress. 29 Our analyses showed some moderate correlations between EASIX and clinical and laboratory parameters to provide a more detailed characterization of EASIX in the context of obstetrics. As expected, parameters and conditions that typically reflect an increased inflammatory status, such as an increased CRP, 30 were significantly associated with EASIX. We observed higher EASIX values in twin pregnancies than in singletons. In studies on sFlt‐1/PlGF ratio and soluble endoglin, twin pregnancies also showed higher levels than singletons. 31 , 32 The increased volume loading in twin pregnancies mandates adaptive cardiac and vascular changes and predisposes for an unmet uteroplacental demand on the cardiovascular system, leading to placental hypoxia and endothelial damage. 33 The inverse correlation between smoking and EASIX values may reflect the paradoxical reduction in preeclampsia incidence among smokers. 34 One proposed mechanism involves elevated TGF‐β1 (transforming growth factor β1) levels in smokers, which may preserve maternal endothelial function by its anti‐inflammatory properties. 35 Prophylactic low‐dose aspirin intake was associated with lower EASIX levels. This observation can be explained with the pleiotropic effects of aspirin on endothelial and platelet function, such as inhibiting cyclooxygenase‐1, and thereby the synthesis of thromboxane. 36 These associations suggest that EASIX further integrates multiple pathophysiological aspects of preeclampsia. Strengths and Limitations We evaluated EASIX in obstetrics and in the context of hypertensive disorders in the largest available study cohort to date. Our primary goal was to further characterize EASIX in obstetrics. Nevertheless, some limitations must be acknowledged. First, given the retrospective design of our study, some information, such as ethnic background, was not consistently available, and an ethnically more diverse population may enhance the generalizability of EASIX. Additionally, the exact date of preeclampsia diagnosis was not always available, hampering the stratification of early versus late‐onset preeclampsia. Second, EASIX was evaluated at 1 center only, without the possibility to compare EASIX with other angiogenic or cardiac markers; thus, further studies are required to validate our findings and to precisely define the synergies and overlaps between existing biomarkers in clinical practice. Our findings should be viewed as hypothesis‐generating, and the derived threshold should not be used for clinical decision‐making without prospective external validation in future studies. CONCLUSIONS We introduced EASIX as a simple score based on the standard laboratory parameters, lactate dehydrogenase, creatinine, and platelet counts that can differentiate between hypertensive disorders of pregnancy. We have shown that EASIX can discriminate between preeclampsia and healthy controls with moderate diagnostic performance. Our analyses provide additional insights into the endothelial dysfunction and the systemic manifestation in preeclampsia, prompting us to explore its incorporation in potential combined biomarker models in clinical routine. Disclosures None. Source of Funding This work was funded by a research grant from the Ernst and Berta Grimmke Foundation (awarded to A.S.S. and A.v.A.). For the publication fee, we acknowledge financial support from Heidelberg University. The funders had no influence on the study design, data collection and analysis, decision to publish, or preparation of the article. Supporting information Figures S1–S5 Tables S1–S2 STROBE Statement–checklist Acknowledgments A.S.S. was supported by the Olympia Morata Program of the Medical Faculty, University of Heidelberg. Parts of the data were presented by L.B. and A.S.S. as a poster presentation at the Congress of the German Society for Perinatal Medicine 2025 (DGPM) and at the Congress of Preeclampsia 2025 in Rostock, Germany. This article was sent to Tochukwu M. Okwuosa, DO, Associate Editor, for review by expert referees, editorial decision, and final disposition. Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.126.049984 For Sources of Funding and Disclosures, see page 9. References Associated Data Supplementary Materials Figures S1–S5 Tables S1–S2 STROBE Statement–checklist